Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea

Cost-effectiveness of vortioxetine versus venlafaxine (extended release) in the treatment of major depressive disorder in South Korea

2016 Expert Rev Pharmacoecon Outcomes Res

Choi, S. E. | Brignone, M. | Cho, S. J. | Jeon, H. J. | Jung, R. | Campbell, R. | Francois, C. | Milea, D. | Volume: 16, Issue: 5, Pages: 629-638, Antidepressive Agents/administration & dosage/economics/*therapeutic use, Cost-Benefit Analysis, Decision Trees, Delayed-Action Preparations, Depressive Disorder, Major/*drug therapy/economics, Humans, Markov Chains, Piperazines/administration & dosage/economics/*therapeutic use, Quality-Adjusted Life Years, Recurrence, Republic of Korea, Sulfides/administration & dosage/economics/*therapeutic use, Time Factors, Treatment Outcome, Venlafaxine Hydrochloride/administration & dosage/economics/*therapeutic use, *Depression, *antidepressant, *cost-effectiveness, *economic, *model,

OBJECTIVE: To assess the cost-effectiveness of vortioxetine versus venlafaxine XR (extended-release) in major depressive disorder (MDD) patients in South Korea. METHODS: A 1-year cost-effectiveness analysis from a limited societal perspective was performed using a combined model consisting of a decision-tree and a Markov model. Patients entered the model when initiating or switching antidepressant treatment following inadequate response to previous treatment. Remission, relapse and recovery were the main health states. RESULTS: Vortioxetine dominated venlafaxine XR, with quality-adjusted life year (QALY) gains of 0.0131 and cost savings of KRW 623,229/year [US$530/year] from a limited societal perspective. Safety contributed more than efficacy to the incremental QALY gains. More patients were in recovery after initial treatment and after 1 year with vortioxetine (31%, 40%) compared to venlafaxine XR (23%, 36%). Vortioxetine remained dominant in 98% of probabilistic simulations. CONCLUSION: Vortioxetine dominated venlafaxine XR in South Korea and is a relevant treatment option for MDD patients initiating or switching therapy.

https://www.doi.org/10.1586/14737167.2016.1128830